These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23032748)

  • 1. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
    Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
    Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
    Li A; Xiong S; Lin Y; Liu R; Chu Y
    DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.
    Qiu J; Li GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W
    Acta Oncol; 2007; 46(7):961-8. PubMed ID: 17917827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
    Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
    Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
    Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
    Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
    Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
    Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
    Conforti A; Cipriani B; Peruzzi D; Dharmapuri S; Kandimalla ER; Agrawal S; Mori F; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2010 Apr; 28(20):3522-30. PubMed ID: 20332048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.